PFGC 2021
Featured articles
Guselkumab shows highest drug survival among systemic treatments
CONTENTS
Online First
Genes in Psoriasis and Psoriatic Arthritis
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Selective IL-23 inhibition normalises gene expression in active PsA
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Comorbidity in Psoriasis
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
Psoriasis Therapy: New Findings
IL-36 gene expression in GPP lesions reduced by spesolimab
Inhibition of heat shock protein: A novel way to treat psoriasis?
Guselkumab shows highest drug survival among systemic treatments
Risankizumab superior to ustekinumab in skin histopathology scores
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
COVID-19: What's New
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Paradoxical Reactions to Biologics
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
